Ravi Salgia to Patient Selection
This is a "connection" page, showing publications Ravi Salgia has written about Patient Selection.
Connection Strength
0.067
-
Early mortality of stage IV non-small cell lung cancer in the United States. Acta Oncol. 2019 Aug; 58(8):1095-1101.
Score: 0.032
-
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011 Oct; 12(11):1004-12.
Score: 0.019
-
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008 Jul; 110(1):49-55.
Score: 0.015